Primary ovarian sarcoma

Autor: Richard E. Buller, Anil K. Sood, Mark S. Gelder, Jo A. Benda, Joel I. Sorosky, Edward J. Wilkinson, Barrie Anderson, Linda S. Morgan
Rok vydání: 1998
Předmět:
Zdroj: Cancer. 82:1731-1737
ISSN: 1097-0142
0008-543X
Popis: BACKGROUND Data regarding the value of cytoreduction and cell histology in ovarian sarcomas are limited. The goal of this study was to assess the value of surgical cytoreduction, preoperative CA 125 levels, stage, histology, and platinum-based chemotherapy in the primary treatment of ovarian sarcomas. METHODS A retrospective analysis of 47 women with primary ovarian sarcomas was performed. RESULTS Forty-one patients (87%) presented with advanced stage disease (International Federation of Gynecology and Obstetrics Stage III or IV). Optimal surgical cytoreduction ( 35 U/mL) in 93% of patients with ovarian sarcomas. A preoperative CA 125 level < 75 U/mL was significantly associated with better survival (P = 0.01). In univariate analysis, other significant predictors of improved survival were early stage (P = 0.04), homologous tumors (P < 0.05), and optimal surgical cytoreduction (P < 0.001). In multivariate analysis of various prognostic variables, optimal surgical cytoreduction (P < 0.001) was the most significant factor, followed by histologic subtype (P < 0.02). CONCLUSIONS Ovarian sarcomas are rare malignancies with a poor prognosis. All women with suspected ovarian carcinoma or sarcoma should have a preoperative CA 125 level taken. Surgical cytoreduction to a residual tumor burden of ≤1 cm improves outcome and should be the goal of surgery. Although the optimal consolidation chemotherapy regimen remains unknown, platinum should be included as part of the regimen. Cancer 1998;82:1731-7. © 1998 American Cancer Society.
Databáze: OpenAIRE
Externí odkaz: